[HTML] frontiersin.org

[HTML][HTML] Evaluation of a Clinically Relevant Drug–Drug Interaction Between Rosuvastatin and Clopidogrel and the Risk of Hepatotoxicity

C Ning, S Su, J Li, D Kong, H Cai, Z Qin… - Frontiers in …, 2021 - frontiersin.org
Purpose: The combination therapy of rosuvastatin (RSV) and the platelet inhibitor
clopidogrel (CP) is widely accepted in the management of cardiovascular diseases. The …
被引用次数：5 相关文章

Evaluation of a Clinically Relevant Drug-Drug Interaction Between Rosuvastatin and Clopidogrel and the Risk of Hepatotoxicity

C Ning, S Su, J Li, D Kong, H Cai… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Purpose: The combination therapy of rosuvastatin (RSV) and the platelet inhibitor
clopidogrel (CP) is widely accepted in the management of cardiovascular diseases. The …

Evaluation of a Clinically Relevant Drug-Drug Interaction Between Rosuvastatin and Clopidogrel and the Risk of Hepatotoxicity.

C Ning, S Su, J Li, D Kong, H Cai, Z Qin… - Frontiers in …, 2021 - europepmc.org
Purpose: The combination therapy of rosuvastatin (RSV) and the platelet inhibitor
clopidogrel (CP) is widely accepted in the management of cardiovascular diseases. The …
[PDF] researchgate.net

[PDF][PDF] Evaluation of a Clinically Relevant Drug–Drug Interaction Between Rosuvastatin and Clopidogrel and the Risk of Hepatotoxicity. Front. Pharmacol. 12: 715577 …

C Ning, S Su, J Li, D Kong, H Cai, Z Qin… - … | www. frontiersin. org, 2021 - researchgate.net
Purpose: The combination therapy of rosuvastatin (RSV) and the platelet inhibitor
clopidogrel (CP) is widely accepted in the management of cardiovascular diseases. The …
[HTML] frontiersin.org

[HTML][HTML] Evaluation of a Clinically Relevant Drug–Drug Interaction Between Rosuvastatin and Clopidogrel and the Risk of Hepatotoxicity

C Ning, S Su, X Chen, J He - Frontiers in Pharmacology, 2021 - frontiersin.org
Purpose: The combination therapy of rosuvastatin (RSV) and the platelet inhibitor
clopidogrel (CP) is widely accepted in the management of cardiovascular diseases. The …
[HTML] nih.gov

[HTML][HTML] Evaluation of a Clinically Relevant Drug–Drug Interaction Between Rosuvastatin and Clopidogrel and the Risk of Hepatotoxicity

C Ning, S Su, J Li, D Kong, H Cai, Z Qin… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
Purpose: The combination therapy of rosuvastatin (RSV) and the platelet inhibitor
clopidogrel (CP) is widely accepted in the management of cardiovascular diseases. The …